Publication at Faculty of Medicine in Hradec Králové |
2022
Abstract
Over the last decade, immunotherapy has been implemented into therapeutic algorithms of various solid tumors including melanoma, renal cancer (RCC) and non-small cell lung cancer (NSCLC). Immunotherapy with checkpoint inhibitors can be administered as both monotherapy or in combination with another checkpoint inhibitor.
However, the risk of immune-related adverse events (irAE) becomes relevant in combined immunotherapy. The growing number of tumors being treated with immunotherapy rises a question whether there are differences across various tumors in terms of irAR incidence and severity.
The aim of this article is to address these issues.